What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?
The Motley Fool
JANUARY 14, 2024
Gene-therapy treatments are growing in popularity, and for a larger healthcare company that is perhaps looking into getting into the business, it could be more attractive to simply buy CRISPR Therapeutics than to develop its own therapies. That's nearly five times the amount of its total liabilities: $359 million.
Let's personalize your content